Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by itntdfon Nov 21, 2022 2:00pm
118 Views
Post# 35116257

RE:RE:RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stock

RE:RE:RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stockthe assignment agreement section starts out with "neither party shall".

both parties to the agreement have rights and interests and both parties have limits regarding what they can and can not do.

Neither Party shall, without the prior written consent of the other Party, assign, novate, transfer or convey this Agreement (in whole or in part) or any of its rights and obligations hereunder to any Third Party ...(subject to...)

i can explain it to you but i just can not understand it for you.  both parties have rights, both parties have obligations, both parties have protections, there is not a "screw off provision" which i can find in the agreement which permits oncy or an acquirer of oncy to just blow adlai off and say your agreement means nothing to me.

that's the whole point of entering into a contract and trusting that neither side will become a "bad actor".  my bias is a general distrust of china and its business practices.  but again, that is the point of a contract to which both sides will agree to abide. 
<< Previous
Bullboard Posts
Next >>